The chemokine network: A target in cancer biology?

Advanced Drug Delivery Reviews

Volumn 58, Issue 8, 2006, Pages 962-974

  Slettenaar, Violet I F ^a   Wilson, Julia L ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Chemokine; Tumor cell

Indexed keywords

ANGIOGRAPHY; CELLS; IMMUNOLOGY; MOLECULAR BIOLOGY; PATHOLOGY;

CHEMOKINE; IMMUNE RESPONSES; TUMOR CELLS;

TUMORS;

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE; CHEMOKINE CCL16; CHEMOKINE CCL17; CHEMOKINE CCL22; CHEMOKINE CCL27; CHEMOKINE CCL3; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; METHIONINE CHEMOKINE CCL5; NEUTRALIZING ANTIBODY; PEPTIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SMALL INTERFERING RNA; TN 14003; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; CELLULAR DISTRIBUTION; COLON ADENOCARCINOMA; DRUG POTENCY; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; LEUKOCYTE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; STOMACH CANCER; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CHEMOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 33751249635     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.03.012     Document Type: Review

References (115)

1. Mackay C.R. Chemokines: immunology's high impact factors. Nat. Immunol. 2 (2001) 95-101
2. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., and Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol. 14 (2004) 155-160
3. Kulbe H., Levinson N.R., Balkwill F., and Wilson J.L. The chemokine network in cancer-much more than directing cell movement. Int. J. Dev. Biol. 48 (2004) 489-496
4. Howard O.M., and Galligan C.L. An expanding appreciation of the role chemokine receptors play in cancer progression. Curr. Pharm. Des. 10 (2004) 2377-2389
5. Conti, and Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 14 (2004) 149-154
6. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
7. Vicari P., and Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 13 (2002) 143-154
8. Murphy P.M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345 (2001) 833-835
9. Negus R.P., Stamp G.W., Hadley J., and Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150 (1997) 1723-1734
10. Milliken D., Scotton C., Raju S., Balkwill F., and Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8 (2002) 1108-1114
11. Scotton C.J., Wilson J.L., Scott K., Stamp G., Wilbanks G.D., Fricker S., Bridger G., and Balkwill F.R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62 (2002) 5930-5938
12. Luboshits G., Shina S., Kaplan O., Engelberg S., Nass D., Lifshitz-Mercer B., Chaitchik S., Keydar I., and Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59 (1999) 4681-4687
13. Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., and Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92 (2001) 1085-1091
14. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., and Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6 (2000) 3282-3289
15. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
16. Cossman, Annunziata C.M., Barash S., Staudt L., Dillon P., He W.W., Ricciardi-Castagnoli P., Rosen C.A., and Carter K.C. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94 (1999) 411-416
17. van den Berg, Visser L., and Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am. J. Pathol. 154 (1999) 1685-1691
18. Bingle, Brown N.J., and Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 (2002) 254-265
19. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001) 727-740
20. Hagemann T., Wilson J., Burke F., Kulbe H., Li N.F., Pludderman A., Charles K., Gordon S., and Balkwill F.R. Ovarian cancer cells polarize macrophages towards a tumor-associated phenotype. J. Immunol. 176 8 (2006) 5023-5032
21. Remmel E., Terracciano L., Noppen C., Zajac P., Heberer M., Spagnoli G.C., and Padovan E. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum. Immunol. 62 (2001) 39-49
22. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D.T., Galanaud P., Capron F., Emilie D., and Curiel T.J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7 (2001) 1339-1346
23. Sozzani S., Luini W., Bianchi G., Allavena P., Wells T.N., Napolitano M., Bernardini G., Vecchi A., 'DAmbrosio D., Mazzeo D., Sinigaglia F., Santoni A., Maggi E., Romagnani S., and Mantovani A. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 92 (1998) 4036-4039
24. Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3 (2003) 643-651
25. Strieter R.M., Belperio J.A., Phillips R.J., and Keane M.P. CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol. 14 (2004) 195-200
26. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., and Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 593-609
27. Mestas J., Burdick M.D., Reckamp K., Pantuck A., Figlin R.A., and Strieter R.M. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J. Immunol. 175 (2005) 5351-5357
28. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., and Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90 (1998) 447-454
29. Veltri R.W., Miller M.C., Zhao G., Ng A., Marley G.M., Wright Jr. G.L., Vessella R.L., and Ralph D. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53 (1999) 139-147
30. Kryczek, Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., Moons L., Wei S., Zou L., Machelon V., Emilie D., Terrassa M., Lackner A., Curiel T.J., Carmeliet P., and Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65 (2005) 465-472
31. Toulza F., Eliaou J.F., and Pinet V. Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines. Int. J. Cancer 115 (2005) 429-436
32. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
33. Spring H., Schuler T., Arnold B., Hammerling G.J., and Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18111-18116
34. Owen D., Strieter R., Burdick M., Haghnegahdar H., Nanney L., Shattuck-Brandt R., and Richmond A. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 73 (1997) 94-103
35. Dhawan P., and Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72 (2002) 9-18
36. Takamori H., Oades Z.G., Hoch O.C., Burger M., and Schraufstatter I.U. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 21 (2000) 52-56
37. Kleeff, Kusama T., Rossi D.L., Ishiwata T., Maruyama H., Friess H., Buchler M.W., Zlotnik A., and Korc M. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81 (1999) 650-657
38. Xu, and Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 12 (2000) 97-106
39. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 14 (2004) 171-179
40. Yasumoto, Koizumi K., Kawashima A., Saitoh Y., Arita Y., Shinohara K., Minami T., Nakayama T., Sakurai H., Takahashi Y., Yoshie O., and Saiki I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 66 (2006) 2181-2187
41. Chinni S.R., Sivalogan S., Dong Z., Filho J.C., Deng X., Bonfil R.D., and Cher M.L. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66 (2006) 32-48
42. Barbero S., Bonavia R., Bajetto A., Porcile C., Pirani P., Ravetti J.L., Zona G.L., Spaziante R., Florio T., and Schettini G. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 63 (2003) 1969-1974
43. Muller, Sonkoly E., Eulert C., Gerber P.A., Kubitza R., Schirlau K., Franken-Kunkel P., Poremba C., Snyderman C., Klotz L.O., Ruzicka T., Bier H., Zlotnik A., Whiteside T.L., Homey B., and Hoffmann T.K. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int. J. Cancer 118 (2005) 2147-2157
44. Zhou Y., Larsen P.H., Hao C., and Yong V.W. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 277 (2002) 49481-49487
45. Zeelenberg S., Ruuls-Van Stalle L., and Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63 (2003) 3833-3839
46. Balkwill F. Chemokine biology in cancer. Semin. Immunol. 15 (2003) 49-55
47. Scotton C.J., Wilson J.L., Milliken D., Stamp G., and Balkwill F.R. Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res. 61 (2001) 4961-4965
48. Cardones R., Murakami T., and Hwang S.T. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta integrin. Cancer Res. 63 (2003) 6751-6757
49. Burger, Glodek A., Hartmann T., Schmitt-Graff A., Silberstein L.E., Fujii N., Kipps T.J., and Burger J.A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22 (2003) 8093-8101
50. Murakami T., Maki W., Cardones A.R., Fang H., Tun Kyi A., Nestle F.O., and Hwang S.T. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62 (2002) 7328-7334
51. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., and Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
52. Allinen, Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., and Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 (2004) 17-32
53. Kaifi T., Yekebas E.F., Schurr P., Obonyo D., Wachowiak R., Busch P., Heinecke A., Pantel K., and Izbicki J.R. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J. Natl. Cancer Inst. 97 (2005) 1840-1847
54. Scala S., Ottaiano A., Ascierto P.A., Cavalli M., Simeone E., Giuliano P., Napolitano M., Franco R., Botti G., and Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 11 (2005) 1835-1841
55. Su, Zhang J., Xu H., Wang Y., Chu Y., Liu R., and Xiong S. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin. Cancer Res. 11 (2005) 8273-8280
56. Schimanski C.C., Schwald S., Simiantonaki N., Jayasinghe C., Gonner U., Wilsberg V., Junginger T., Berger M.R., Galle P.R., and Moehler M. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res. 11 (2005) 1743-1750
57. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., Pienta K.J., and Taichman R.S. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 89 (2003) 462-473
58. Cabioglu, Yazici M.S., Arun B., Broglio K.R., Hortobagyi G.N., Price J.E., and Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin. Cancer Res. 11 (2005) 5686-5693
59. Hu J., Deng X., Bian X., Li G., Tong Y., Li Y., Wang Q., Xin R., He X., Zhou G., Xie P., Wang J.M., and Cao Y. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin. Cancer Res. 11 (2005) 4658-4665
60. Laverdiere C., Hoang B.H., Yang R., Sowers R., Qin J., Meyers P.A., Huvos A.G., Healey J.H., and Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin. Cancer Res. 11 (2005) 2561-2567
61. Airoldi, Raffaghello L., Piovan E., Cocco C., Carlini B., Amadori A., Corrias M.V., and Pistoia V. CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications. Clin. Cancer Res. 12 (2006) 77-82
62. Weigelt B., Wessels L.F., Bosma A.J., Glas A.M., Nuyten D.S., He Y.D., Dai H., Peterse J.L., and van't Veer L.J. No common denominator for breast cancer lymph node metastasis. Br. J. Cancer 93 (2005) 924-932
63. Muller, Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
64. Mashino, Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., Inoue H., and Mori M. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62 (2002) 2937-2941
65. Ding Y., Shimada Y., Maeda M., Kawabe A., Kaganoi J., Komoto I., Hashimoto Y., Miyake M., Hashida H., and Imamura M. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9 (2003) 3406-3412
66. Takanami. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer 105 (2003) 186-189
67. Wang, Xi L., Hunt J.L., Gooding W., Whiteside T.L., Chen Z., Godfrey T.E., and Ferris R.L. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 64 (2004) 1861-1866
68. Wiley H.E., Gonzalez E.B., Maki W., Wu Mt M.T., and Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93 (2001) 1638-1643
69. Wang, Zhang X., Thomas S.M., Grandis J.R., Wells A., Chen Z.G., and Ferris R.L. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 24 (2005) 5897-5904
70. Tsuzuki H., Takahashi N., Kojima A., Narita N., Sunaga H., Takabayashi T., and Fujieda S. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris, Nasus, Larynx (2005)
71. Gunther, Leier J., Henning G., Dimmler A., Weissbach R., Hohenberger W., and Forster R. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int. J. Cancer 116 (2005) 726-733
72. Singh S., Singh U.P., Stiles J.K., Grizzle W.E., and Lillard Jr. J.W. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin. Cancer Res. 10 (2004) 8743-8750
73. Letsch, Keilholz U., Schadendorf D., Assfalg G., Asemissen A.M., Thiel E., and Scheibenbogen C. Functional CCR9 expression is associated with small intestinal metastasis. J. Invest. Dermatol. 122 (2004) 685-690
74. Johrer, Zelle-Rieser C., Perathoner A., Moser P., Hager M., Ramoner R., Gander H., Holtl L., Bartsch G., Greil R., and Thurnher M. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin. Cancer Res. 11 (2005) 2459-2465
75. Kawada, Sonoshita M., Sakashita H., Takabayashi A., Yamaoka Y., Manabe T., Inaba K., Minato N., Oshima M., and Taketo M.M. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 64 (2004) 4010-4017
76. Vaday G.G., Peehl D.M., Kadam P.A., and Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 (2006) 124-134
77. Ishida T., Utsunomiya A., Iida S., Inagaki H., Takatsuka Y., Kusumoto S., Takeuchi G., Shimizu S., Ito M., Komatsu H., Wakita A., Eimoto T., Matsushima K., and Ueda R. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9 (2003) 3625-3634
78. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., and Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64 (2004) 4693-4698
79. Monti, Leone B.E., Marchesi F., Balzano G., Zerbi A., Scaltrini F., Pasquali C., Calori G., Pessi F., Sperti C., Di Carlo V., Allavena P., and Piemonti L. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 63 (2003) 7451-7461
80. Moran C.J., Arenberg D.A., Huang C.C., Giordano T.J., Thomas D.G., Misek D.E., Chen G., Iannettoni M.D., Orringer M.B., Hanash S., and Beer D.G. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8 (2002) 3803-3812
81. Kondo T., Ito F., Nakazawa H., Horita S., Osaka Y., and Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J. Urol. 171 (2004) 2171-2175
82. Nakanishi T., Imaizumi K., Hasegawa Y., Kawabe T., Hashimoto N., Okamoto M., and Shimokata K. Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol. Immunother. (2006) 1-10
83. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., Batra R.K., and Dubinett S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164 (2000) 4558-4563
84. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., Taub D.T., Iannettoni M.D., Whyte R.I., and Strieter R.M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184 (1996) 981-992
85. Crittenden, Gough M., Harrington K., Olivier K., Thompson J., and Vile R.G. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 63 (2003) 5505-5512
86. Braun S.E., Chen K., Foster R.G., Kim C.H., Hromas R., Kaplan M.H., Broxmeyer H.E., and Cornetta K. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164 (2000) 4025-4031
87. Fushimi T., Kojima A., Moore M.A., and Crystal R.G. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105 (2000) 1383-1393
88. Vicari P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., and Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165 (2000) 1992-2000
89. Lavergne E., Combadiere C., Iga M., Boissonnas A., Bonduelle O., Maho M., Debre P., and Combadiere B. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 173 (2004) 3755-3762
90. Hensbergen J., Wijnands P.G., Schreurs M.W., Scheper R.J., Willemze R., and Tensen C.P. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J. Immunother. 28 (2005) 343-351
91. Zeng Y., Jiang J., Huebener N., Wenkel J., Gaedicke G., Xiang R., and Lode H.N. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 228 (2005) 187-193
92. Shurin G.V., Ferris R., Tourkova I.L., Perez L., Lokshin A., Balkir L., Collins B., Chatta G.S., and Shurin M.R. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174 (2005) 5490-5498
93. Frederick J., Henderson Y., Xu X., Deavers M.T., Sahin A.A., Wu H., Lewis D.E., El-Naggar A.K., and Clayman G.L. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am. J. Pathol. 156 (2000) 1937-1950
94. Guiducci C., Di Carlo E., Parenza M., Hitt M., Giovarelli M., Musiani P., and Colombo M.P. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol. 172 (2004) 4026-4036
95. Okada, Gao J.Q., Sasaki A., Niwa M., Okada Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Fujita T., Yamamoto A., Tsutsumi Y., Mayumi T., and Nakagawa S. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochem. Biophys. Res. Commun. 317 (2004) 68-76
96. Gough, Crittenden M., Thanarajasingam U., Sanchez-Perez L., Thompson J., Jevremovic D., and Vile R. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J. Immunol. 174 (2005) 5766-5773
97. Parker J.N., Meleth S., Hughes K.B., Gillespie G.Y., Whitley R.J., and Markert J.M. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 12 (2005) 359-368
98. Roda J.M., Parihar R., Magro C., Nuovo G.J., Tridandapani S., and Carson III W.E. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 66 (2006) 517-526
99. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Morris S.B., Xue Y.Y., Burdick M.D., Glass M.C., Iannettoni M.D., and Strieter R.M. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102 (1998) 465-472
100. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., and Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97 (1996) 2792-2802
101. Mian B.M., Dinney C.P., Bermejo C.E., Sweeney P., Tellez C., Yang X.D., Gudas J.M., McConkey D.J., and Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin. Cancer Res. 9 (2003) 3167-3175
102. Robinson C., Scott K.A., Wilson J.L., Thompson R.G., Proudfoot A.E., and Balkwill F.R. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63 (2003) 8360-8365
103. Wente N., Keane M.P., Burdick M.D., Friess H., Buchler M.W., Ceyhan G.O., Reber H.A., Strieter R.M., and Hines O.J. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. (2006)
104. Bertolini F., Dell'Agnola C., Mancuso P., Rabascio C., Burlini A., Monestiroli S., Gobbi A., Pruneri G., and Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 62 (2002) 3106-3112
105. Guleng B., Tateishi K., Ohta M., Kanai F., Jazag A., Ijichi H., Tanaka Y., Washida M., Morikane K., Fukushima Y., Yamori T., Tsuruo T., Kawabe T., Miyagishi M., Taira K., Sata M., and Omata M. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res. 65 (2005) 5864-5871
106. Rubin J.B., Kung A.L., Klein R.S., Chan J.A., Sun Y., Schmidt K., Kieran M.W., Luster A.D., and Segal R.A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13513-13518
107. Retz, Sidhu S.S., Lehmann J., Tamamura H., Fujii N., and Basbaum C. New HIV-drug inhibits in vitro bladder cancer migration and invasion. Eur. Urol. 48 (2005) 1025-1030
108. Takenaga, Tamamura H., Hiramatsu K., Nakamura N., Yamaguchi Y., Kitagawa A., Kawai S., Nakashima H., Fujii N., and Igarashi R. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun. 320 (2004) 226-232
109. Mori, Doi R., Koizumi M., Toyoda E., Ito D., Kami K., Masui T., Fujimoto K., Tamamura H., Hiramatsu K., Fujii N., and Imamura M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. 3 (2004) 29-37
110. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., and Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64 (2004) 4302-4308
111. Chen Y., Stamatoyannopoulos G., and Song C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 63 (2003) 4801-4804
112. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., and Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65 (2005) 967-971
113. Snyder E.L., Saenz C.C., Denicourt C., Meade B.R., Cui X.S., Kaplan I.M., and Dowdy S.F. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res. 65 (2005) 10646-10650
114. Johnson Z., Schwarz M., Power C.A., Wells T.N., and Proudfoot A.E. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol. 26 (2005) 268-274
115. Coscia, and Biragyn A. Cancer immunotherapy with chemoattractant peptides. Semin. Cancer Biol. 14 (2004) 209-218